HUP0401104A2 - Dipeptidil-peptidáz inhibitorként cukorbetegség megelőzésére és kezelésére alkalmazható (béta-aminoacil)-tetrahidroimidazo[1,2-a]pirazinok és - tetrahidrotriazolo[4,3-a]pirazinok, valamint az ezeket tartalmazó gyógyszerkészítmények - Google Patents

Dipeptidil-peptidáz inhibitorként cukorbetegség megelőzésére és kezelésére alkalmazható (béta-aminoacil)-tetrahidroimidazo[1,2-a]pirazinok és - tetrahidrotriazolo[4,3-a]pirazinok, valamint az ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0401104A2
HUP0401104A2 HU0401104A HUP0401104A HUP0401104A2 HU P0401104 A2 HUP0401104 A2 HU P0401104A2 HU 0401104 A HU0401104 A HU 0401104A HU P0401104 A HUP0401104 A HU P0401104A HU P0401104 A2 HUP0401104 A2 HU P0401104A2
Authority
HU
Hungary
Prior art keywords
pyrazines
diabetes
tetrahydrotriazolo
tetrahydroimidazo
aminoacyl
Prior art date
Application number
HU0401104A
Other languages
English (en)
Inventor
Scott D. Edmondson
Michael H. Fisher
Dooseop Kim
Malcolm Maccoss
Emma R. Parmee
Ann E. Weber
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23172273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0401104(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of HUP0401104A2 publication Critical patent/HUP0401104A2/hu
Publication of HUP0401104A3 publication Critical patent/HUP0401104A3/hu
Publication of HU225695B1 publication Critical patent/HU225695B1/hu
Priority to HUS0700005C priority Critical patent/HUS0700005I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Az (I) általános képletű vegyületek - a képletben Ar jelentésefenilcsoport, amely szubsztituálatlan, vagy 1-5 R3 csoporttal vanszubsztituálva; X jelentése N, vagy CR2; R1 és R2 jelentése egymústólfüggetlenül hidrogénatom, CN, vagy adott esetben szubsztituált 1-10szénatomos alkil-, fenil- vagy 5- vagy 6-tagú heterociklusos csoport adipeptidil-peptidáz-IV enzim inhibitorai, ezért olyan betegségekmegelőzésére vagy kezelésére alkalmazhatók, amelyekben a dipeptidil-peptidáz-IV enzim szerepet játszik, ilyen például a cukorbetegség,különösen a II. típusú cukorbetegség. A találmány a fenti vegyületekettartalmazó gyógyászati készítményekre, valamint a fenti készítményekés vegyületek gyógyászati alkalmazására is vonatkozik. Ó
HU0401104A 2001-07-06 2002-07-05 Dipeptidil-peptidáz-inhibitorként cukorbetegség megelõzésére és kezelésére alkalmazható (béta-amino-acil)-tetrahidroimidazo[1,2-a]pirazinok és -tetrahidrotriazolo[4,3-a]pirazinok, valamint az ezeket tartalmazó gyógyszerkészítmények HU225695B1 (hu)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HUS0700005C HUS0700005I1 (hu) 2001-07-06 2007-08-22 Dipeptidil-peptidáz-inhibitorként cukorbetegség megelõzésére és kezelésére alkalmazható (béta-amino-acil)-tetrahidroimidazo[1,2-a]pirazinok és -tetrahidrotriazolo[4,3-a]pirazinok, valamint az ezeket tartalmazó gyógyszerkészítmények

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30347401P 2001-07-06 2001-07-06
PCT/US2002/021349 WO2003004498A1 (en) 2001-07-06 2002-07-05 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Publications (3)

Publication Number Publication Date
HUP0401104A2 true HUP0401104A2 (hu) 2004-09-28
HUP0401104A3 HUP0401104A3 (en) 2006-02-28
HU225695B1 HU225695B1 (hu) 2007-06-28

Family

ID=23172273

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0401104A HU225695B1 (hu) 2001-07-06 2002-07-05 Dipeptidil-peptidáz-inhibitorként cukorbetegség megelõzésére és kezelésére alkalmazható (béta-amino-acil)-tetrahidroimidazo[1,2-a]pirazinok és -tetrahidrotriazolo[4,3-a]pirazinok, valamint az ezeket tartalmazó gyógyszerkészítmények
HUS0700005C HUS0700005I1 (hu) 2001-07-06 2007-08-22 Dipeptidil-peptidáz-inhibitorként cukorbetegség megelõzésére és kezelésére alkalmazható (béta-amino-acil)-tetrahidroimidazo[1,2-a]pirazinok és -tetrahidrotriazolo[4,3-a]pirazinok, valamint az ezeket tartalmazó gyógyszerkészítmények

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS0700005C HUS0700005I1 (hu) 2001-07-06 2007-08-22 Dipeptidil-peptidáz-inhibitorként cukorbetegség megelõzésére és kezelésére alkalmazható (béta-amino-acil)-tetrahidroimidazo[1,2-a]pirazinok és -tetrahidrotriazolo[4,3-a]pirazinok, valamint az ezeket tartalmazó gyógyszerkészítmények

Country Status (46)

Country Link
US (9) US7125873B2 (hu)
EP (4) EP1625847B1 (hu)
JP (1) JP3762407B2 (hu)
KR (1) KR100606871B1 (hu)
CN (2) CN1290848C (hu)
AR (1) AR036114A1 (hu)
AT (2) ATE321048T1 (hu)
AU (1) AU2002320303B2 (hu)
BE (1) BE2007C047I2 (hu)
BG (1) BG108493A (hu)
BR (1) BRPI0210866B8 (hu)
CA (1) CA2450740C (hu)
CR (1) CR7235A (hu)
CY (3) CY2007019I2 (hu)
DE (4) DE122007000056I1 (hu)
DK (2) DK1412357T3 (hu)
DO (1) DOP2002000438A (hu)
EA (2) EA006845B1 (hu)
EC (1) ECSP044935A (hu)
ES (2) ES2259713T3 (hu)
FR (2) FR07C0041I2 (hu)
GE (2) GEP20063734B (hu)
HK (1) HK1068882A1 (hu)
HR (1) HRP20031098B1 (hu)
HU (2) HU225695B1 (hu)
IL (3) IL159109A0 (hu)
IS (2) IS2218B (hu)
JO (1) JO2230B1 (hu)
LT (1) LTC1412357I2 (hu)
LU (2) LUC91360I2 (hu)
MA (1) MA27053A1 (hu)
ME (1) ME00439B (hu)
MX (1) MXPA04000018A (hu)
MY (1) MY127961A (hu)
NL (2) NL300287I2 (hu)
NO (4) NO321999B1 (hu)
NZ (1) NZ529833A (hu)
PE (1) PE20030654A1 (hu)
PL (1) PL196278B6 (hu)
PT (2) PT1412357E (hu)
RS (1) RS50737B (hu)
SI (1) SI1412357T1 (hu)
TW (1) TWI226331B (hu)
UA (1) UA74912C2 (hu)
WO (1) WO2003004498A1 (hu)
ZA (1) ZA200309294B (hu)

Families Citing this family (429)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US7544511B2 (en) * 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
US20030176357A1 (en) * 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
DE69915514T2 (de) * 1998-12-31 2005-01-05 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Prenyltransferase-inhibitoren
JP2004535433A (ja) 2001-06-20 2004-11-25 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療用のジペプチジルペプチダーゼ阻害薬
DE60209348T2 (de) 2001-06-20 2006-10-12 Merck & Co., Inc. Dipeptidylpeptidase-hemmer zur behandlung von diabetes
MXPA03011907A (es) 2001-06-27 2004-03-26 Smithkline Beecham Corp Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
EP1476178A4 (en) * 2002-02-14 2009-08-26 Bayer Pharmaceuticals Corp FORMULATION STRATEGIES IN STABILIZING PEPTIDES IN ORGANIC SOLVENTS AND DRY CONDITIONS
US7307164B2 (en) * 2002-03-25 2007-12-11 Merck & Co., Inc. β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JP4530852B2 (ja) * 2002-07-15 2010-08-25 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4491346B2 (ja) 2002-10-07 2010-06-30 メルク・シャープ・エンド・ドーム・コーポレイション 抗糖尿病ベータアミノ複素環ジペプチジルペプチダーゼ阻害剤
KR20050067418A (ko) * 2002-10-18 2005-07-01 머크 앤드 캄파니 인코포레이티드 당뇨병을 치료 또는 예방하기 위한 베타-아미노헤테로사이클릭 디펩티딜 펩티다제 억제제
MXPA05004890A (es) 2002-11-07 2005-07-22 Merck & Co Inc Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevencion de diabetes.
JP2006510630A (ja) * 2002-12-04 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
AU2003293409A1 (en) * 2002-12-09 2004-06-30 Karl K. Johe Method for discovering neurogenic agents
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
AU2003294824A1 (en) * 2002-12-10 2004-06-30 Novartis Ag Combination of an dpp-iv inhibitor and a ppar-alpha compound
AU2003297219A1 (en) * 2002-12-20 2004-07-22 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
PT1599468E (pt) 2003-01-14 2008-01-14 Arena Pharm Inc Derivados de arilo e heteroarilo 1,2,3.-trissubstituídos comomoduladores do metabolismo, e profilaxia e tratamento dedesordens relacionadas tais como diabetes e hiperglicemia
JP4564952B2 (ja) * 2003-01-17 2010-10-20 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004069162A2 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AR043443A1 (es) * 2003-03-07 2005-07-27 Merck & Co Inc Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios
AR043505A1 (es) * 2003-03-18 2005-08-03 Merck & Co Inc Preparacion de beta-cetoamidas e intermediarios de reaccion
AR043515A1 (es) * 2003-03-19 2005-08-03 Merck & Co Inc Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
WO2004085661A2 (en) * 2003-03-24 2004-10-07 Merck & Co., Inc Process to chiral beta-amino acid derivatives
CA2518465A1 (en) * 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2004087650A2 (en) * 2003-03-27 2004-10-14 Merck & Co. Inc. Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
ATE462432T1 (de) 2003-05-05 2010-04-15 Probiodrug Ag Glutaminylcyclase-hemmer
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
DE602004023932D1 (de) * 2003-05-14 2009-12-17 Merck & Co Inc 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
ATE463492T1 (de) * 2003-06-06 2010-04-15 Merck Sharp & Dohme Kondensierte indole als dipeptidyl-peptidase- hemmer zur behandlung oder prävention von diabetes
WO2004110375A2 (en) * 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of diabetes
JP4579239B2 (ja) * 2003-06-17 2010-11-10 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療または予防するためのジペプチジルペプチダーゼ阻害剤としてのシクロヘキシルグリシン誘導体
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN102417508A (zh) 2003-07-14 2012-04-18 艾尼纳制药公司 作为新陈代谢调节剂的稠合芳基和杂芳基衍生物以及预防和治疗与其相关的病症
PL1648933T3 (pl) * 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Długo działające pochodne insuliny i związane z tym sposoby
WO2005011581A2 (en) * 2003-07-31 2005-02-10 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050070531A1 (en) * 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
EP1662876A4 (en) * 2003-09-02 2009-01-14 Merck & Co Inc NOVEL CRYSTALLINE FORMS OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
JP2007513058A (ja) * 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
JP2007505121A (ja) * 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
US20070021430A1 (en) * 2003-09-23 2007-01-25 Chen Alex M Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US20070123470A1 (en) * 2003-10-24 2007-05-31 Wladimir Hogenhuis Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005044195A2 (en) * 2003-11-04 2005-05-19 Merck & Co., Inc. Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
KR100918322B1 (ko) * 2003-11-12 2009-09-22 페노믹스 코포레이션 헤테로시클릭 보론산 화합물
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
KR20130105741A (ko) 2003-11-17 2013-09-25 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
WO2005072530A1 (en) * 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
PT3366283T (pt) 2004-01-20 2021-12-02 Novartis Ag Formulação e processo de compressão direta
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
CN101684089A (zh) * 2004-02-05 2010-03-31 杏林制药株式会社 双环酯类衍生物
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
JPWO2005077900A1 (ja) * 2004-02-18 2007-10-18 杏林製薬株式会社 ビシクロアミド誘導体
EP1719757B1 (en) * 2004-02-27 2013-10-09 Kyorin Pharmaceutical Co., Ltd. Bicyclo derivative
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005095381A1 (en) 2004-03-15 2005-10-13 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1732904B1 (en) 2004-03-29 2014-03-19 Merck Sharp & Dohme Corp. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
TW200602293A (en) 2004-04-05 2006-01-16 Merck & Co Inc Process for the preparation of enantiomerically enriched beta amino acid derivatives
CN1950349A (zh) * 2004-05-04 2007-04-18 默克公司 作为用于治疗或预防糖尿病的二肽基肽酶－ⅳ抑制剂的1,2,4－噁二唑衍生物
EP1756106A4 (en) * 2004-05-18 2008-12-17 Merck & Co Inc CYCLOHEXYLALANINE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2005118555A1 (en) * 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1761532B1 (en) * 2004-06-21 2013-04-10 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CN101087756B (zh) * 2004-07-23 2011-04-06 纽阿达有限责任公司 肽酶抑制剂
TW200608967A (en) 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
ATE472531T1 (de) 2004-08-06 2010-07-15 Merck Sharp & Dohme Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
US7625888B2 (en) 2004-08-23 2009-12-01 Merck & Co., Inc. Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
JP4854511B2 (ja) * 2004-08-26 2012-01-18 武田薬品工業株式会社 糖尿病治療剤
PE20060652A1 (es) 2004-08-27 2006-08-11 Novartis Ag Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion
EP1796671A4 (en) * 2004-09-15 2009-01-21 Merck & Co Inc AMORPHOUS FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
ATE481969T1 (de) 2004-10-01 2010-10-15 Merck Sharp & Dohme Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
CA2583457C (en) * 2004-10-12 2013-01-29 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
IN2014CN03629A (hu) * 2004-11-17 2015-09-04 Neuralstem Inc
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US8017633B2 (en) * 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
TWI357902B (en) 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth
AU2006242219A1 (en) * 2005-05-02 2006-11-09 Merck & Co., Inc. Combination of dipeptidyl peptidase-IV inhibitor and a cannabinoid CB1 receptor antagonist for the treatment of diabetes and obesity
CN101500573A (zh) * 2005-05-25 2009-08-05 默克公司 用于糖尿病治疗或者预防的作为二肽基肽酶-ⅳ抑制剂的氨基环己烷
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
JP5154927B2 (ja) 2005-05-30 2013-02-27 Ｍｓｄ株式会社 新規ピペリジン誘導体
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
JP4915833B2 (ja) * 2005-07-01 2012-04-11 雪印メグミルク株式会社 ジペプチジルペプチダーゼｉｖ阻害剤
ES2391470T3 (es) * 2005-07-20 2012-11-27 Eli Lilly And Company Compuestos de fenilo
ES2325558T3 (es) 2005-07-20 2009-09-08 Eli Lilly And Company Derivados de piridina como inhibidores de dipeptidilpeptidasa.
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
WO2007035198A2 (en) * 2005-07-25 2007-03-29 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
US7875633B2 (en) 2005-08-24 2011-01-25 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
US20070060528A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
RS52110B2 (sr) 2005-09-14 2018-05-31 Takeda Pharmaceuticals Co Inhibitori dipeptidil peptidaze za lečenje dijabetesa
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
WO2007035629A2 (en) 2005-09-16 2007-03-29 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
JP2009513633A (ja) * 2005-10-25 2009-04-02 メルク エンド カムパニー インコーポレーテッド 糖尿病および高血圧を治療するためのジペプチジルペプチダーゼ−４インヒビターと降圧薬との組合せ
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHIIN DERIVATIVES
AU2006312557B2 (en) 2005-11-10 2011-12-08 Msd K.K. Aza-substituted spiro derivative
AU2006333151B2 (en) * 2005-12-16 2010-03-04 Merck Sharp & Dohme Llc Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
US20090042863A1 (en) * 2005-12-28 2009-02-12 Takeda Pharmaceutical Company Limited Therapeutic Agent for Diabetes
EA200801591A1 (ru) * 2005-12-30 2008-12-30 Рэнбакси Лабораториз Лимитед Антагонисты мускаринового рецептора
US20090156465A1 (en) 2005-12-30 2009-06-18 Sattigeri Jitendra A Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
AU2007208405B2 (en) * 2006-01-25 2011-05-26 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2007102286A1 (ja) * 2006-03-08 2007-09-13 Kyorin Pharmaceutical Co., Ltd. アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2009531456A (ja) * 2006-03-28 2009-09-03 武田薬品工業株式会社 （ｒ）−３−アミノピペリジン二塩酸塩の調製
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
WO2007115821A2 (en) 2006-04-11 2007-10-18 Novartis Ag Organic compounds
EA201101475A1 (ru) 2006-04-11 2012-07-30 Арена Фармасьютикалз, Инк. Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
MEP8509A (en) 2006-09-07 2011-12-20 Combination treatment for diabetes mellitus
MY145447A (en) * 2006-09-13 2012-02-15 Takeda Pharmaceutical Use of 2-6(3-amino-piperidin-1-yl)-3-methyl-2, 4-dioxo-3, 4-dihydrp-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
WO2008047544A1 (fr) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Dérivé diarylcétimine
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
KR20080071476A (ko) * 2007-01-30 2008-08-04 주식회사 엘지생명과학 신규한 디펩티딜 펩티데이즈 ｉｖ(ｄｐｐ-ｉｖ) 저해제
NZ579008A (en) * 2007-02-01 2012-02-24 Takeda Pharmaceutical Solid preparation comprising alogliptin and pioglitazone
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
JPWO2008114857A1 (ja) * 2007-03-22 2010-07-08 杏林製薬株式会社 アミノアセチルピロリジンカルボニトリル誘導体の製造方法
WO2008120653A1 (ja) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. インドールジオン誘導体
US8927504B2 (en) 2007-04-03 2015-01-06 Mitsubishi Tanabe Pharma Corporation Combined use of dipeptidyl peptidase 4 inhibitor and sweetener
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2155187B1 (en) 2007-05-07 2016-05-25 Merck Sharp & Dohme Corp. Method of treatment using fused aromatic compounds having anti-diabetic activity
WO2008141021A1 (en) * 2007-05-08 2008-11-20 Concert Pharmaceuticals, Inc. Deuterated derivatives of tetrahydrotriazolopyrazine compounds and their use as dpp-iv inhibitors
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008149346A2 (en) 2007-06-04 2008-12-11 Ben Gurion University Of The Negev Research And Development Authority Enhanced sensitivity polymerase chain reactions
CN101318922B (zh) * 2007-06-08 2010-11-10 上海阳帆医药科技有限公司 一类二肽基肽酶抑制剂、合成方法和用途
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
RU2569749C2 (ru) * 2007-08-17 2015-11-27 Бёрингер Ингельхайм Интернациональ Гмбх Производные пурина, предназначенные для применения для лечения заболеваний, связанных с баф (белок-активатор фибробластов)
CN101397300B (zh) * 2007-09-04 2011-04-27 山东轩竹医药科技有限公司 二肽酶-ⅳ抑制剂衍生物
US20090076013A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched sitagliptin
CN101417999A (zh) * 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
US8334385B2 (en) * 2007-11-02 2012-12-18 Glenmark Generics Limited Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof
US20090192326A1 (en) * 2007-11-13 2009-07-30 Nurit Perlman Preparation of sitagliptin intermediate
CN101903390A (zh) 2007-12-20 2010-12-01 雷迪博士实验室有限公司 制备西他列汀及其药学上可接受的盐的方法
UA103181C2 (ru) * 2007-12-21 2013-09-25 Ел Джи Лайф Сайєнсіз, Лтд. Соединения, которые ингибируют дипептидилпептидазу-iv и фармацевтическая композиция, которая содержит их как активный агент
CN101468988A (zh) * 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
EP2250157B1 (en) 2008-01-24 2014-11-05 Panacea Biotec Limited Novel heterocyclic compounds
EP2249643A4 (en) * 2008-02-05 2013-10-09 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF A METFORMIN AND DIPEPTIDYL PEPTIDASE-IV INHIBITOR ASSOCIATION
MX2010009731A (es) * 2008-03-04 2010-09-30 Merck Sharp & Dohme Composiciones farmaceuticas de una combinacion de metformina y un inhibidor de dipeptidil peptidasa-iv.
EP2264026A4 (en) 2008-03-06 2012-03-28 Msd Kk ALKYLAMINOPYRIDINE DERIVATIVE
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
US20090247532A1 (en) * 2008-03-28 2009-10-01 Mae De Ltd. Crystalline polymorph of sitagliptin phosphate and its preparation
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
EP2108960A1 (en) * 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
US20090264476A1 (en) * 2008-04-18 2009-10-22 Mckelvey Craig CB-1 receptor modulator formulations
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
US8003672B2 (en) * 2008-04-21 2011-08-23 Merck Sharp & Dohme Corp. CB-1 receptor modulator formulations
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2727914A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diaryl ketoxime derivative technical field
CA2729696A1 (en) 2008-07-03 2010-01-07 Ratiopharm Gmbh Crystalline salts of sitagliptin
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2010012781A2 (en) * 2008-07-29 2010-02-04 Medichem, S.A. New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
WO2010016584A1 (ja) * 2008-08-07 2010-02-11 杏林製薬株式会社 ビシクロ[２．２．２]オクチルアミン誘導体の製造方法
KR20110044780A (ko) * 2008-08-14 2011-04-29 교린 세이야꾸 가부시키 가이샤 안정화된 의약 조성물
US8476437B2 (en) * 2008-08-27 2013-07-02 Cadila Healthcare Limited Process for preparation of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine and new impurities in preparation thereof
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
CA2738663A1 (en) 2008-10-03 2010-04-08 Schering Corporation Spiro-imidazolone derivatives as glucagon receptor antagonists
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101054911B1 (ko) * 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
PE20110852A1 (es) 2008-10-30 2011-11-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
EP2358200A4 (en) 2008-11-17 2012-05-16 Merck Sharp & Dohme BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
WO2010078440A1 (en) * 2008-12-31 2010-07-08 Chiral Quest, Inc. Process and intermediates for the preparation of n-acylated-4-aryl beta-amino acid derivatives
WO2010079433A2 (en) * 2009-01-07 2010-07-15 Glenmark Pharmaceuticals, S.A. Pharmaceutical composition that includes a dipeptidyl peptidase-iv inhibitor
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
UY32048A (es) 2009-01-08 2010-03-26 Boehringer Ingelheim Int Derivados sustituido de 1-(sustituido)-3-metil-7-(sustituido)-8-(3-(R)-amino-piperidin-1-il)cantina y derivados sustituidos de 1-(sustituido) - 4 - fluoropirrolidin- 2 - carbonitrilo y sus sales famacéuticamente aceptables como inhibidores de DPP-4 y aplicaciones.
PT2376447T (pt) 2009-01-09 2017-11-15 Orchid Pharma Ltd Inibidores de dipeptidil-peptidase iv
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
EP2218721A1 (en) * 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Novel salts of sitagliptin
EP2395988A2 (en) 2009-02-13 2011-12-21 Boehringer Ingelheim International GmbH Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
WO2010092125A1 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
EP2223923A1 (en) 2009-02-25 2010-09-01 Esteve Química, S.A. Process for the preparation of a chiral beta aminoacid derivative and intermediates thereof
CN101824036A (zh) * 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
PL2415753T3 (pl) 2009-03-30 2015-03-31 Dong A Pharm Co Ltd Sposób wytwarzania inhibitora peptydazy dipeptydylowej IV oraz związku pośredniego
BRPI1014070B8 (pt) 2009-03-30 2021-05-25 Dong A Pharm Co Ltd processos para a produção de inibidor de dipeptidil peptidase-iv e intermediário
CN101849944A (zh) * 2009-03-31 2010-10-06 江苏恒瑞医药股份有限公司 治疗2型糖尿病的药物组合物
WO2010122578A2 (en) * 2009-04-20 2010-10-28 Msn Laboratories Limited Process for the preparation of sitagliptin and its intermediates
NZ596713A (en) * 2009-05-11 2014-10-31 Generics Uk Ltd Sitagliptin synthesis
CN101899047B (zh) * 2009-05-26 2016-01-20 盛世泰科生物医药技术(苏州)有限公司 作为二肽基肽酶抑制剂用于治疗或预防糖尿病的β-氨基四氢吡嗪、四氢嘧啶和四氢吡啶
CN101899048B (zh) * 2009-05-27 2013-04-17 上海恒瑞医药有限公司 (R)-7-[3-氨基-4-(2,4,5-三氟-苯基)-丁酰]-3-三氟甲基-5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸甲酯的盐
EP2440553B1 (en) 2009-06-12 2017-08-23 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
IT1395596B1 (it) * 2009-06-30 2012-10-16 Dipharma Francis Srl Procedimento per la preparazione di sitagliptin
AR077463A1 (es) 2009-07-09 2011-08-31 Irm Llc Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011508A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
JP5916387B2 (ja) 2009-08-03 2016-05-11 株式会社カネカ ジペプチジルペプチダーゼ−４阻害剤
EP2464648B1 (de) * 2009-08-13 2016-09-21 Sandoz AG Kristalline Verbindung von 7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorphenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluormethyl)-1,2,4-triazolo[4,3-a]pyrazin
EP2464228B1 (en) 2009-08-13 2017-12-06 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2011028455A1 (en) 2009-09-02 2011-03-10 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
EP2295083A1 (de) 2009-09-15 2011-03-16 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin
CN102030683B (zh) * 2009-09-27 2013-07-31 浙江九洲药业股份有限公司 西他列汀中间体及其制备方法和用途
EP2308847B1 (en) 2009-10-09 2014-04-02 EMC microcollections GmbH Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases
AU2010317842A1 (en) 2009-11-16 2012-07-12 Mellitech [1,5]-diazocin derivatives
KR20210033559A (ko) 2009-11-27 2021-03-26 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011079778A1 (en) 2009-12-30 2011-07-07 China Shanghai Fochon Pharmaceutical Co Ltd 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
KR101156587B1 (ko) 2010-02-19 2012-06-20 한미사이언스 주식회사 시타글립틴의 제조방법 및 이에 사용되는 아민염 중간체
WO2011103256A1 (en) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
CZ303113B6 (cs) 2010-03-16 2012-04-11 Zentiva, K.S. Zpusob prípravy sitagliptinu
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CA2800507A1 (en) 2010-03-31 2011-10-06 Teva Pharmaceuticals Industries Ltd. Solid state forms of sitagliptin salts
US9029567B2 (en) * 2010-04-05 2015-05-12 Cadila Pharmaceuticals Limited Hypoglycemic compounds
BR112012025592A2 (pt) 2010-04-06 2019-09-24 Arena Pharm Inc moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
CA2796327A1 (en) 2010-04-28 2011-11-03 Sun Pharmaceutical Industries Ltd. Process for the preparation of chiral beta-amino carboxamide derivatives
PT2566469T (pt) 2010-05-05 2023-01-10 Boehringer Ingelheim Int Terapia de combinação
WO2011146358A1 (en) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
CN102260265B (zh) 2010-05-24 2015-09-02 上海阳帆医药科技有限公司 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
EP2392575A1 (en) 2010-06-04 2011-12-07 LEK Pharmaceuticals d.d. A novel synthetic approach to ß-aminobutyryl substituted compounds
WO2011151443A1 (en) 2010-06-04 2011-12-08 Lek Pharmaceuticals D.D. A NOVEL SYNTHETIC APPROACH TO ß-AMINOBUTYRYL SUBSTITUTED COMPOUNDS
EP2397141A1 (en) 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Process for the synthesis of beta-amino acids and derivatives thereof
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
EP2407469A1 (en) 2010-07-13 2012-01-18 Chemo Ibérica, S.A. Salt of sitagliptin
EP2423178A1 (en) 2010-07-28 2012-02-29 Chemo Ibérica, S.A. Process for the production of sitagliptin
CN103237553A (zh) 2010-07-28 2013-08-07 神经干细胞公司 治疗和/或逆转神经退行性疾病和/或病症的方法
EP2418196A1 (en) * 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
EP2605658B1 (en) 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
EP2609099A2 (en) 2010-08-27 2013-07-03 USV Limited Sitagliptin, salts and polymorphs thereof
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2012035549A2 (en) 2010-09-13 2012-03-22 Panacea Biotec Ltd An improved process for the synthesis of beta amino acid derivatives
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
JP2013541942A (ja) * 2010-10-08 2013-11-21 カディラ ヘルスケア リミティド 酵素的変換によるシタグリプチンの中間体を生産する方法
WO2012049566A1 (en) 2010-10-14 2012-04-19 Japan Tobacco Inc. Combination therapy for use in treating diabetes
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102485718B (zh) 2010-12-03 2014-03-26 浙江海翔药业股份有限公司 西他列汀的中间体及其制备方法
US8691832B2 (en) 2010-12-06 2014-04-08 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
WO2012076973A2 (en) 2010-12-09 2012-06-14 Aurobindo Pharma Limited Novel salts of dipeptidyl peptidase iv inhibitor
TWI494313B (zh) * 2010-12-29 2015-08-01 Jiangsu Hengrui Medicine Co 治療包括人類之哺乳動物中第２型糖尿病的醫藥組成物
CN103597071A (zh) 2011-01-07 2014-02-19 埃尔舍利克斯治疗公司 基于化学感应受体配体的治疗
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
KR101290029B1 (ko) 2011-01-20 2013-07-30 에스티팜 주식회사 시타글립틴의 중간체 제조방법
MY191100A (en) 2011-01-31 2022-05-30 Cadila Healthcare Ltd Treatment for lipodystrophy
KR101668514B1 (ko) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
EP2860180A1 (en) * 2011-03-03 2015-04-15 Cadila Healthcare Limited Novel gentisate salts of DPP-IV inhibitor
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
SI2691083T1 (sl) 2011-03-29 2017-12-29 Krka, D.D., Novo Mesto Farmacevtski sestavek sitagliptina
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012138845A1 (en) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
KR101369584B1 (ko) 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
CN102757431B (zh) * 2011-04-24 2016-03-30 浙江华海药业股份有限公司 一种合成西他列汀的新方法
ITMI20110765A1 (it) * 2011-05-05 2012-11-06 Chemo Iberica Sa Processo per la produzione di sitagliptina
US8524936B2 (en) 2011-05-18 2013-09-03 Milan Soukup Manufacturing process for sitagliptin from L-aspartic acid
EP2527320A1 (en) 2011-05-27 2012-11-28 LEK Pharmaceuticals d.d. Preparation of Sitagliptin Intermediates
US9359385B2 (en) * 2011-05-27 2016-06-07 Lek Pharmaceuticals D.D. Preparation of sitagliptin intermediates
MX2013014161A (es) 2011-06-02 2014-03-21 Intervet Int Bv Derivados de imidazol.
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
AR086675A1 (es) * 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
AU2012271009A1 (en) 2011-06-16 2013-11-14 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
JP5873554B2 (ja) 2011-06-29 2016-03-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． キラルジペプチジルペプチダーゼ−ｉｖ阻害剤の調製プロセス
EP2726484A1 (en) 2011-06-29 2014-05-07 Ranbaxy Laboratories Limited Solid dispersions of sitagliptin and processes for their preparation
CA2840806A1 (en) 2011-06-30 2013-01-03 Ranbaxy Laboratories Limited Novel salts of sitagliptin
WO2013006526A2 (en) 2011-07-05 2013-01-10 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013013833A1 (en) 2011-07-27 2013-01-31 Farma Grs, D.O.O. Process for the preparation of sitagliptin and its pharmaceutically acceptable salts
EA201490556A1 (ru) 2011-09-07 2014-08-29 Сановел Илач Санайи Ве Тиджарет Аноним Ширкети Составы ингибитора дпп-4
WO2013048916A1 (en) 2011-09-30 2013-04-04 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
PL2578208T3 (pl) 2011-10-06 2014-10-31 Sanovel Ilac Sanayi Ve Ticaret As Stałe formulacje dawkowane inhibitora DPP-IV
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013054364A2 (en) * 2011-10-14 2013-04-18 Laurus Labs Private Limited Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
EP2771000B1 (en) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
CN102603749B (zh) * 2011-10-27 2017-02-08 浙江华海药业股份有限公司 一种西他列汀中间体的合成方法
WO2013065066A1 (en) 2011-11-02 2013-05-10 Cadila Healthcare Limited Processes for preparing 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro [l,2,41-triazolo[43-a]pyrazin-7(8h)-yl]-l-(2,4,5- trifluorophenyl)butan-2-amine
WO2013068328A1 (en) 2011-11-07 2013-05-16 Intervet International B.V. Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
WO2013068439A1 (en) 2011-11-09 2013-05-16 Intervet International B.V. 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
WO2013074388A1 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
US20140350023A1 (en) 2011-12-08 2014-11-27 Ranbaxy Laboratories Limited Amorphous form of sitagliptin salts
KR102231554B1 (ko) 2012-01-06 2021-03-23 앤지 파마 유에스 엘엘씨 대사 장애를 치료하는 조성물 및 방법
KR102035879B1 (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
US9073930B2 (en) 2012-02-17 2015-07-07 Merck Sharp & Dohme Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
ES2421956B1 (es) 2012-03-02 2014-09-29 Moehs Ibérica S.L. Nueva forma cristalina de sulfato de sitagliptina
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
IN2014DN09640A (hu) 2012-04-16 2015-07-31 Kaneq Pharma Inc
TWI469785B (zh) 2012-04-25 2015-01-21 Inovobiologic Inc 用於治療代謝性疾病之膳食纖維組成物
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2674432A1 (en) 2012-06-14 2013-12-18 LEK Pharmaceuticals d.d. New synthetic route for the preparation of ß aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha]pyrazin-7-yl compounds
WO2014018350A1 (en) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-iv inhibitors
US9156848B2 (en) 2012-07-23 2015-10-13 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014023930A1 (en) 2012-08-08 2014-02-13 Cipla Limited Process for the preparation of sitagliptin and intermediate compounds
CN102898387B (zh) * 2012-09-26 2015-01-07 浙江工业大学 管道化连续生产n-[(2z)-哌嗪-2-亚基]-2,2,2-三氟乙酰肼的方法
TWI500613B (zh) 2012-10-17 2015-09-21 Cadila Healthcare Ltd 新穎之雜環化合物
CN103788070B (zh) * 2012-10-26 2017-10-20 南京华威医药科技开发有限公司 Dpp‑4抑制剂类多聚物
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CZ306115B6 (cs) * 2012-12-04 2016-08-10 Zentiva, K.S. Způsob přípravy derivátů kyseliny 3-amino-4-(2,4,5-trifluorfenyl)-butanové
CN103319487B (zh) * 2013-01-10 2015-04-01 药源药物化学（上海）有限公司 西格列汀的制备方法及其中间体
EP2769712A1 (en) 2013-02-21 2014-08-27 Siegfried International AG Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
CN105669682B (zh) * 2013-02-22 2019-08-30 成都先导药物开发股份有限公司 一种dpp-iv抑制剂的中间体
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
IN2013MU00916A (hu) 2013-03-20 2015-06-26 Cadila Healthcare Ltd
AU2013387996B2 (en) 2013-04-22 2015-12-10 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (NAFLD)
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
EP4424697A2 (en) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015001568A2 (en) * 2013-07-01 2015-01-08 Laurus Labs Private Limited Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (hu) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (hu) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CZ2013842A3 (cs) 2013-11-01 2015-05-13 Zentiva, K.S. Stabilní polymorf soli (2R)-4-oxo-4-[3-(trifluorometyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorofenyl)butan-2-aminu s kyselinou L-vinnou
CR20160207A (es) 2013-11-05 2016-08-10 Ben Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad
CN103626775B (zh) * 2013-12-02 2015-05-20 南京华威医药科技开发有限公司 具有二嗪结构的dpp-4抑制剂
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
WO2015114657A2 (en) 2014-01-21 2015-08-06 Cadila Healthcare Limited Amorphous form of sitagliptin free base
US10065945B2 (en) 2014-01-24 2018-09-04 Merck Sharp & Dohme Corp. Isoquinoline derivatives as MGAT2 inhibitors
IN2014MU00651A (hu) 2014-02-25 2015-10-23 Cadila Healthcare Ltd
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2015145333A1 (en) 2014-03-26 2015-10-01 Sun Pharmaceutical Industries Limited Process for the preparation of sitagliptin and its intermediate
US9833463B2 (en) 2014-04-17 2017-12-05 Merck Sharp & Dohme Corp. Sitagliptin tannate complex
WO2015162506A1 (en) 2014-04-21 2015-10-29 Suven Life Sciences Limited Process for the preparation of sitagliptin and novel intermediates
WO2015170340A2 (en) * 2014-05-06 2015-11-12 Laurus Labs Private Limited Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9862725B2 (en) 2014-07-21 2018-01-09 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitors
WO2016022448A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CN104140430B (zh) * 2014-08-08 2016-07-13 广东东阳光药业有限公司 一种异构体的消旋方法
WO2016022742A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
WO2016046679A1 (en) * 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of diabetes and pre-diabetes
CA2964927C (en) 2014-10-20 2019-07-30 Neuralstem, Inc. Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
WO2016110750A1 (en) 2015-01-08 2016-07-14 Lee Pharma Limited Novel process for the preparation of dipeptidyl peptidase-4 (dpp-4) enzyme inhibitor
CZ27930U1 (cs) 2015-01-13 2015-03-10 Zentiva, K.S. Krystalická modifikace 3 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
CZ27898U1 (cs) 2015-01-13 2015-03-02 Zentiva, K.S. Krystalická modifikace 2 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4,]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
EP3267994A4 (en) 2015-03-09 2018-10-31 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP2018512436A (ja) * 2015-04-15 2018-05-17 バレント・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＶａｌｅｎｔ ＢｉｏＳｃｉｅｎｃｅｓ ＬＬＣ （ｓ）−２’−ビニル−アブシジン酸誘導体
KR101772898B1 (ko) 2015-06-11 2017-08-31 동방에프티엘(주) 시타글립틴의 개선된 제조방법
KR101709127B1 (ko) 2015-06-16 2017-02-22 경동제약 주식회사 Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
CN108349891B (zh) 2015-06-22 2022-04-05 艾尼纳制药公司 用于s1p1受体相关病症的化合物的结晶l-精氨酸盐
CN105017260B (zh) * 2015-07-30 2017-04-19 新发药业有限公司 一种西他列汀中间体三唑并吡嗪衍生物的制备方法
US11000521B2 (en) 2015-08-03 2021-05-11 Institut Pasteur Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
KR20180064403A (ko) * 2015-09-09 2018-06-14 와렌 씨. 라우 신규한 fyn 키나제 억제제의 방법, 조성물, 및 용도
KR20170036288A (ko) 2015-09-24 2017-04-03 주식회사 종근당 시타글립틴의 신규염 및 이의 제조방법
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
EP3159343B1 (en) * 2015-10-22 2017-07-19 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of triazole and salt thereof
EP3383869B1 (en) 2015-11-30 2023-06-28 Merck Sharp & Dohme LLC Aryl sulfonamides as blt1 antagonists
US20190382363A1 (en) 2015-11-30 2019-12-19 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
WO2017201683A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물
US10414774B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease
US10414775B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
CN106124667B (zh) * 2016-08-29 2018-07-31 上海应用技术学院 一种分离测定西格列汀有关物质的方法
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
MX2016016260A (es) 2016-12-08 2018-06-07 Alparis Sa De Cv Nuevas formas solidas de sitagliptina.
EP3551180B1 (en) 2016-12-09 2021-09-29 Cadila Healthcare Limited Treatment for primary biliary cholangitis
WO2018107415A1 (en) 2016-12-15 2018-06-21 Merck Sharp & Dohme Corp. Hydroxy isoxazole compounds useful as gpr120 agonists
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US11197949B2 (en) * 2017-01-19 2021-12-14 Medtronic Minimed, Inc. Medication infusion components and systems
US10047094B1 (en) 2017-02-10 2018-08-14 F.I.S.—Fabbrica Italiana Sintetici S.p.A. Process for the preparation of triazole and salt thereof
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
MX2019011867A (es) 2017-04-03 2020-01-09 Coherus Biosciences Inc Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva.
MX2019012758A (es) 2017-04-24 2019-12-16 Novartis Ag Regimen terapeutico de 2-amino-1-(2-(4-fluorofenil)-3-(4-fluorofen ilamino)-8,8-dimetil-5,6-dihidroimidazo [1,2-a]pirazin-7(8h)-il)et anona y combinaciones de la misma.
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
US11096890B2 (en) 2017-09-29 2021-08-24 Merck Sharp & Dohme Corp. Chewable dosage forms containing sitagliptin and metformin
KR20190060235A (ko) 2017-11-24 2019-06-03 제일약품주식회사 시타글립틴 캄실산염의 제조방법
TR201722603A2 (tr) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
CN108586346B (zh) 2018-05-10 2019-10-01 北京富盛嘉华医药科技有限公司 一种生物催化合成西他列汀及其中间体的方法
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP3946324A4 (en) 2019-04-04 2022-11-30 Merck Sharp & Dohme LLC HISTONE DEACETYLASE-3 INHIBITORS USEFUL FOR THE TREATMENT OF CANCER, INFLAMMATION, NEURODEGENERATIVE DISEASES AND DIABETES
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
EP4045048A4 (en) 2019-10-14 2023-05-24 Santa Farma Ilaç Sanayi A.S. ORAL FORMULATIONS COMPRISING SITAGLIPTIN HCI MONOHYDRATE WITH ENHANCED PHARMACEUTICAL CHARACTERISTICS
KR20210057603A (ko) 2019-11-12 2021-05-21 제이투에이치바이오텍 (주) 시타글립틴의 제조방법
AU2021329805B2 (en) 2020-08-18 2024-02-29 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists
KR102589305B1 (ko) 2021-04-22 2023-10-16 주식회사 메디켐코리아 시타글립틴 인산염의 개선된 제조방법
CN113979896A (zh) * 2021-11-18 2022-01-28 浙江永太手心医药科技有限公司 一种西格列汀杂质i及其制备方法
WO2023139276A1 (en) 2022-01-24 2023-07-27 Zaklady Farmaceutyczne Polpharma S.A. Process for preparing crystalline sitagliptin hydrochloride monohydrate
WO2024086263A1 (en) 2022-10-21 2024-04-25 Merck Sharp & Dohme Llc Compositions of a dipeptidyl peptidase-iv inhibitor and an antioxidant
WO2024121301A1 (en) 2022-12-09 2024-06-13 Krka, D.D., Novo Mesto Process for the preparation of sitagliptin
EP4431087A1 (en) 2023-03-14 2024-09-18 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet of sitagliptin or a pharmaceutically acceptable salt thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB9324803D0 (en) * 1993-12-03 1994-01-19 Ferring Bv Enzyme inhibitors
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU9651198A (en) 1997-11-11 1999-05-31 Ono Pharmaceutical Co. Ltd. Fused pyrazine compounds
IL139247A0 (en) 1998-05-04 2001-11-25 Point Therapeutics Inc Hematopoietic stimulation
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
FR2780974B1 (fr) 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
DE60012721D1 (de) 1999-03-29 2004-09-09 Uutech Ltd Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
JP2002541146A (ja) 1999-04-02 2002-12-03 ニューロゲン コーポレイション アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用
DE60023492T2 (de) 1999-05-17 2006-07-20 Novo Nordisk A/S Glucagon antagonisten/inverse agonisten
CZ296858B6 (cs) 1999-09-28 2006-07-12 Bayer Corporation Agonisté receptoru 3 (R3) hypofyzárního peptidu aktivujícího adenylátcyklázu (PACAP) a jejich farmaceutické pouzití
JP2003535034A (ja) 1999-11-12 2003-11-25 ギルフォード ファーマシューティカルズ インコーポレイテッド ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
WO2002002560A2 (en) 2000-07-04 2002-01-10 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7307164B2 (en) * 2002-03-25 2007-12-11 Merck & Co., Inc. β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP4491346B2 (ja) * 2002-10-07 2010-06-30 メルク・シャープ・エンド・ドーム・コーポレイション 抗糖尿病ベータアミノ複素環ジペプチジルペプチダーゼ阻害剤
WO2004069162A2 (en) * 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Also Published As

Publication number Publication date
PL196278B1 (pl) 2007-12-31
US20110190308A1 (en) 2011-08-04
EP1412357B1 (en) 2006-03-22
EP1625847A1 (en) 2006-02-15
EA012701B1 (ru) 2009-12-30
US20150359793A1 (en) 2015-12-17
EA200501805A1 (ru) 2006-06-30
IL159109A0 (en) 2004-05-12
RS50737B (sr) 2010-08-31
ME00439B (me) 2011-12-20
HUP0401104A3 (en) 2006-02-28
MY127961A (en) 2007-01-31
PL196278B6 (pl) 2023-02-13
US20060270679A1 (en) 2006-11-30
EP1625847B1 (en) 2010-06-16
GEP20053734B (en) 2006-01-10
IL178307A (en) 2010-04-15
EP2292232A1 (en) 2011-03-09
US6699871B2 (en) 2004-03-02
NL300287I2 (nl) 2009-04-01
DE60236767D1 (de) 2010-07-29
NL300357I1 (nl) 2008-10-01
AU2002320303B2 (en) 2004-10-14
CY2008014I2 (el) 2009-11-04
BR0210866A (pt) 2004-06-29
CY1110784T1 (el) 2015-06-10
NL300357I2 (nl) 2009-01-05
HRP20031098B1 (en) 2012-03-31
PT1412357E (pt) 2006-07-31
CN1290848C (zh) 2006-12-20
AR036114A1 (es) 2004-08-11
US8440668B2 (en) 2013-05-14
EA200400153A1 (ru) 2004-06-24
UA74912C2 (en) 2006-02-15
IS2218B (is) 2007-03-15
DE60210093T2 (de) 2006-11-23
JP3762407B2 (ja) 2006-04-05
LTC1412357I2 (lt) 2021-01-11
NO2008013I2 (no) 2011-01-24
EP2292232B1 (en) 2014-08-20
DK1625847T3 (da) 2010-10-18
JP2004536115A (ja) 2004-12-02
NL300287I1 (nl) 2007-10-01
DE122007000056I1 (de) 2007-12-13
ATE471148T1 (de) 2010-07-15
NO2007010I1 (no) 2007-09-17
CN1524082A (zh) 2004-08-25
IS2964B (is) 2017-02-15
FR08C0033I1 (hu) 2008-09-26
LUC91360I1 (hu) 2020-04-23
NO2020007I1 (no) 2020-03-19
ATE321048T1 (de) 2006-04-15
NO321999B1 (no) 2006-07-31
BE2007C047I2 (hu) 2021-06-04
BRPI0210866B1 (pt) 2016-07-05
US20130217695A1 (en) 2013-08-22
US8168637B2 (en) 2012-05-01
FR07C0041I1 (hu) 2007-10-19
EP1412357A1 (en) 2004-04-28
PL367279A1 (en) 2005-02-21
ZA200309294B (en) 2004-07-22
US20040167133A1 (en) 2004-08-26
IL159109A (en) 2007-06-03
DK1412357T3 (da) 2006-07-17
PT1625847E (pt) 2010-08-20
NZ529833A (en) 2005-01-28
GEP20063734B (en) 2006-01-10
NO2008013I1 (no) 2008-09-08
LUC91360I2 (hu) 2020-06-12
US20170348309A1 (en) 2017-12-07
JO2230B1 (en) 2004-10-07
HK1068882A1 (en) 2005-05-06
HRP20031098A2 (en) 2004-06-30
US20030100563A1 (en) 2003-05-29
HUS0700005I1 (hu) 2022-01-28
CR7235A (es) 2006-05-31
US20200206221A1 (en) 2020-07-02
TWI226331B (en) 2005-01-11
KR100606871B1 (ko) 2006-08-01
MA27053A1 (fr) 2004-12-20
CA2450740A1 (en) 2003-01-16
LU91470I2 (fr) 2008-10-20
SI1412357T1 (sl) 2006-06-30
ES2344846T3 (es) 2010-09-08
IS7062A (is) 2003-11-28
IS8617A (is) 2007-03-06
YU100603A (sh) 2006-05-25
FR07C0041I2 (fr) 2016-09-30
MXPA04000018A (es) 2004-05-21
CN1861077A (zh) 2006-11-15
US7125873B2 (en) 2006-10-24
CY2007019I1 (el) 2009-11-04
PE20030654A1 (es) 2003-07-29
NO20040021L (no) 2004-01-05
CY2007019I2 (el) 2017-07-12
US20100130504A1 (en) 2010-05-27
HU225695B1 (hu) 2007-06-28
EP2226324A1 (en) 2010-09-08
ECSP044935A (es) 2004-02-26
DE60210093D1 (de) 2006-05-11
CA2450740C (en) 2006-02-14
ES2259713T3 (es) 2006-10-16
FR08C0033I2 (fr) 2010-12-31
LTPA2007006I1 (lt) 2020-04-27
NO2007010I2 (no) 2009-12-14
DOP2002000438A (es) 2003-01-31
CY2008014I1 (el) 2009-11-04
BRPI0210866B8 (pt) 2021-05-25
EA006845B1 (ru) 2006-04-28
WO2003004498A1 (en) 2003-01-16
BG108493A (en) 2005-04-30
KR20040010842A (ko) 2004-01-31
DE122008000046I1 (de) 2009-02-05

Similar Documents

Publication Publication Date Title
HUP0401104A2 (hu) Dipeptidil-peptidáz inhibitorként cukorbetegség megelőzésére és kezelésére alkalmazható (béta-aminoacil)-tetrahidroimidazo[1,2-a]pirazinok és - tetrahidrotriazolo[4,3-a]pirazinok, valamint az ezeket tartalmazó gyógyszerkészítmények
HUP0400365A2 (hu) 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0303391A2 (hu) Alifás, nitrogéntartalmú 5-tagú gyűrűs vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EP1490335A4 (en) HETEROCYCLIC BETA-AMINO DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
EP1554280A4 (en) ANTIDIABETIC HETEROCYCLIC BETA AMINO BINDINGS AS INHIBITORS OF DIPEPTIDYLPEPTIDASE
IL133825A0 (en) Substituted 6-phenylphenanthridines, medicaments containing same and use thereof
HUP0302792A2 (hu) Dipeptidil peptidáz ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
MY120064A (en) Indole derivatives as inhibitors or factor xa
HK1086265A1 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE60310991D1 (de) Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
PT1280797E (pt) Inibidores da peptidase iv de dipeptidilo
HUP0004559A1 (hu) Ciklinfüggő kinázok aminotiazol inhibitorai, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BG106020A (en) Inhibitors of impdh enzyme
HUP0202795A2 (hu) Pirimidin- és pirazinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0302960A2 (hu) Kemokinreceptorhoz kötődő heterociklusos vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
MXPA05000388A (es) Derivados de flavona como inhibidores de cinasas dependientes de la ciclina.
EP1651623A4 (en) HEXAHYDRODIAZEPINONES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OR PREVENTION OF DIABETES
RS101304A (sr) Indolni, azaindolni i srodni heterociklični 4-alkenil piperidinski amidi
GEP20053626B (en) Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof
SE9702534D0 (sv) Compounds
TW200500338A (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Legal Events

Date Code Title Description
AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/07/383/001-018 20070321

Spc suppl protection certif: S0700005

Filing date: 20070822

Expiry date: 20220705

AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS (MAINLY MONOPHOSPHATE) AND ; REG. NO/DATE: EU/1/08/455/001-014 20080716; FIRST REG.: CH 58450/01-03 20080408

Spc suppl protection certif: S0800009

Filing date: 20080819

Expiry date: 20220705

GB9A Succession in title

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): MERCK & CO., INC., US

FG4S Grant of supplementary protection certificate

Free format text: PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS (MAINLY MONOPHOSPHATE) AND ; REG. NO/DATE: EU/1/08/455/001-014 20080716; FIRST REG.: CH 58450/01-03 20080408

Spc suppl protection certif: S0800009

Filing date: 20080819

Expiry date: 20220705

Extension date: 20230409

GB9A Succession in title

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): MERCK & CO., INC., US; MERCK SHARP & DOHME CORP., US

FG4S Grant of supplementary protection certificate

Spc suppl protection certif: S0700005

Filing date: 20070822

Expiry date: 20220705

Extension date: 20220923

GB9A Succession in title